Viewing nowGabamed Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
NBK Pharmaceutical Co., Ltd.

MFDS item code 201800719 · Approved 2018.02.06 · Insurance code 054800080
Treatment of neuropathic pain and fibromyalgia, and adjunctive treatment of partial seizures in epilepsy
This medication is used in adults to treat peripheral and central neuropathic pain. It is also effective as an adjunct for treating partial seizures in epileptic patients. Additionally, it helps relieve symptoms of fibromyalgia, making it effective for improving symptoms of various nerve-related conditions.
This drug is administered orally, with or without food, in 2 divided doses per day of the total daily dose of pregabalin. Since this drug is primarily excreted by the kidneys, the dose must be adjusted in patients with impaired renal function. (See section '5. Patients with renal impairment') 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section '4. Discontinuation of treatment') 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is primarily excreted unchanged by the kidneys. Since the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose according to renal function TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under method of administration. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
7. Pediatric and adolescent patients Administration is not recommended in children under 12 years of age or adolescents aged 12 ~17 years because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal ideation or behavior; thus, patients should consult a doctor immediately if they experience changes in mood or symptoms of depression while taking it. Patients with hypersensitivity to any of the ingredients or certain genetic conditions such as lactose intolerance should not take this medication. Diabetic patients may experience weight gain after taking this medication, and dosage adjustment may be necessary for blood sugar control. If symptoms of angioedema occur, such as swelling of the face or around the mouth, stop taking the medication immediately and notify a healthcare professional. Elderly patients may experience increased dizziness or drowsiness while taking this medication, so caution is advised until they become accustomed to its effects. This medication may cause blurred vision or changes in vision; if such symptoms occur, consult a healthcare professional. Withdrawal symptoms like insomnia, headache, and anxiety may occur when discontinuing the medication, so it is advisable to taper off slowly under a doctor's guidance. Patients with a history of drug abuse may have a higher risk of misuse of this medication and should take special care while using it. Patients with severe heart disease should consult a doctor before taking this medication, and caution is advised if taken in conjunction with opioid analgesics due to the risk of central nervous system depression. This medication may cause respiratory depression, so patients with respiratory or neurological diseases, as well as the elderly, may require dose adjustment. During early pregnancy, this medication may affect the fetus, so women who are pregnant or planning to become pregnant should consult a doctor before taking it. Lactating women should consult a doctor about the use of this medication since it may be transmitted through breast milk. Dizziness or drowsiness may occur when driving or operating machinery; it is safest to avoid these activities until such symptoms are confirmed. In case of overdose, symptoms such as confusion, drowsiness, and seizures may occur, so the prescribed dosage must be strictly adhered to, and if overdose is suspected, seek medical attention immediately. This medication should be kept out of reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent air or moisture from entering, in a cool place between 15 to 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for a longer time.
A hard capsule with a white body and cap containing white powder
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
NBK Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.